The results of this pilot clinical study provide the first evidence of the potential role of reduced endothelial expression of EPCR, an anticoagulant with anti-inflammatory properties, as a biomarker of endothelial and vascular dysfunction in peripheral artery disease. This evidence concerns the gene PROCR and peripheral arterial disease.